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Genome-wide DNA methylation 
detection by MethylCap-seq and 
Infinium HumanMethylation450 
BeadChips: an independent large-
scale comparison
Tim De Meyer1, Pierre Bady2,3,4, Geert Trooskens1, Sebastian Kurscheid2,3,5,†, 
Jocelyne Bloch5, Johan M. Kros6, Johannes A. Hainfellner7, Roger Stupp5,8, 
Mauro Delorenzi3,4, Monika E. Hegi2,5 & Wim Van Criekinge1
Two cost-efficient genome-scale methodologies to assess DNA-methylation are MethylCap-seq and 
Illumina’s Infinium HumanMethylation450 BeadChips (HM450). Objective information regarding the 
best-suited methodology for a specific research question is scant. Therefore, we performed a large-
scale evaluation on a set of 70 brain tissue samples, i.e. 65 glioblastoma and 5 non-tumoral tissues. 
As MethylCap-seq coverages were limited, we focused on the inherent capacity of the methodology 
to detect methylated loci rather than a quantitative analysis. MethylCap-seq and HM450 data were 
dichotomized and performances were compared using a gold standard free Bayesian modelling 
procedure. While conditional specificity was adequate for both approaches, conditional sensitivity 
was systematically higher for HM450. In addition, genome-wide characteristics were compared, 
revealing that HM450 probes identified substantially fewer regions compared to MethylCap-seq. 
Although results indicated that the latter method can detect more potentially relevant DNA-
methylation, this did not translate into the discovery of more differentially methylated loci between 
tumours and controls compared to HM450. Our results therefore indicate that both methodologies 
are complementary, with a higher sensitivity for HM450 and a far larger genome-wide coverage for 
MethylCap-seq, but also that a more comprehensive character does not automatically imply more 
significant results in biomarker studies.
DNA-methylation is an epigenetic feature that is essential for a variety of biological processes, including 
imprinting, X-chromosome inactivation, differentiation and development. In humans, the methylation 
of cytosines particularly occurs at CpG-dinucleotides, which are often grouped in so-called CpG-islands, 
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and is catalyzed by DNA methyltransferases. Gene promoter hypermethylation is typically associated 
with gene silencing, but recent research is demonstrating a more complex role with additional func-
tions of non-promoter methylation in e.g. splicing, and relevant methylation of regions surrounding 
CpG-islands, namely CpG-island shores and shelves1.
Per definition, epigenetic marks can be mitotically inherited, which is crucial to maintain a stable 
expression signature. On the other hand, deviant DNA-methylation patterns have been demonstrated 
in a plethora of diseases, with cancer as particular example2–5. The high-throughput assessment of 
DNA-methylation across the genome is therefore not only crucial to deepen our insight in the regula-
tion of biological processes as for instance gene expression, differentiation and development, but also to 
identify pathology associated aberrations, which might have potential clinical applications.
State-of-the-art methods to detect DNA-methylation on a genome-scale can be roughly divided into 
bisulfite and methylation enrichment based methods. Upon bisulfite treatment, unmethylated cytosines 
are deaminated into uracils, with subsequent basepairing behavior of thymines, whereas methylated 
cytosines remain intact3,6. The introduced sequence differences can be exploited using e.g. whole genome 
sequencing of bisulfite modified DNA, allowing a straightforward methylation quantification for each 
cytosine. Whole genome bisulfite sequencing is however cost-inefficient7, particularly in multi-sample 
studies. As a solution, only targeted regions of the genome are assessed with methods such as reduced 
representation bisulfite sequencing (RRBS)8 and targeted bisulfite sequencing9, or with the use of arrays.
The latter solution has been implemented in Illumina’s Infinium HumanMethylation BeadChips, 
which rely on the quantitative measurement of bisulfite induced (i.e. methylation status dependent) sin-
gle nucleotide polymorphisms. The most recent generation BeadChips, HumanMethylation450, which 
we will further refer to as “HM450” , consist of two assay types, i.e. types 1 and 2. The HM450 type 1 
assay employs two probes per CpG locus: one “methylated” and one “unmethylated” query probe located 
on corresponding “methylated” and “unmethylated” beads, respectively. After hybridization with the 
matching probe, single base extension incorporating a labeled nucleotide at the 3′ probe terminus will 
provoke either the “methylated” (M) or “unmethylated” (U) signal (same color channel, but on different 
beads). HM450 type 2 assays employ a single degenerate probe type that hybridizes to both variants, 
but different colors/channels are used to quantify and differentiate either methylated and unmethylated 
alleles10. Type 2 assays assess a far larger part of the genome, but it has been reported that the data dis-
tributions of the estimated methylation degrees differ between both assay types and that HM450 type 2 
assay probe results are generally inferior11–14.
For both types of chemistries, methylation degrees are typically calculated as β -values, i.e. β = M/
(U + M + α ), with α a constant offset value (typically 100)10,13. Additionally, detection P-values are gen-
erated for each locus, indicating whether the result is reliable10. The combination of the rather straight-
forward data-analysis, good performance and low cost, has made Illumina’s HM450 (one of) the most 
popular tool(s) to assess DNA-methylation, although only in a human context and on a “genome-scale”, 
i.e. only a fraction of the full genome is assessed. An additional drawback is the fact that accurate probe 
design is complicated by the presence of SNPs, and that probes often lack specificity15. Though the raw 
data appear to be already highly reproducible16, additional preprocessing may further improve overall 
results and different widely used R Bioconductor packages are available for this purpose, e.g. lumi17 and 
minfi18.
An alternative cost-efficient, putatively genome-wide, option is to assess only methylated fragments, 
and is more broadly applicable than human-centric studies. Methylated DNA-fragments can be cap-
tured, after fragmentation, using either antibodies (methylated DNA immunoprecipitation, MeDIP)19 
or Methyl-Binding Domains (MBD)20,21. Subsequent deep sequencing (MeDIP-seq or MBD-seq/
MethylCap-seq) results in a genome-wide overview of each sample’s methylome. Here, the number of 
sequenced fragments for a specific locus is a proxy for its methylation degree. Although irrelevant for 
most studies - that typically compare the corresponding loci between cases and controls to identify differ-
entially methylated regions - it should be noted that the number of fragments detected by these methods 
depends on the underlying CpG-density22.
This bias was observed in a recent study evaluating MeDIP-seq, MethylCap-seq, RRBS, and Infinium 
HumanMethylation27 BeadChips (“HM27”)22. This comparison also suggested that the MethylCap-seq 
methodology yielded the largest number of differentially methylated loci, whereas this was the lowest 
for the BeadChips. However, this study was based on a very limited sample set, and only considered the 
former HM27 which has a far more limited genomic coverage (~27,500 loci) than the currently widely 
used HM450 assay (~485,000 loci). HM450 has been compared with the cost-inefficient whole-genome 
bisulfite sequencing methodology, but only by the commercial developers of HM450 10. Therefore, we 
present an independent, large-scale comparison of HM450 with the previously best performing and 
affordable MethylCap-seq methodology, which allows further insights into the methodologies’ sensitivity 
and specificity and genome-wide character. For this comparison, we analyzed a total of 70 brain tissue 
samples, including 65 glioblastoma and 5 non-tumoral brain tissues.
Results
Summary statistics for the HM450 and MethylCap-seq data for each of the 70 brain tissue samples (65 
glioblastoma and 5-non tumoral samples) are available in Supplementary Table S1. Average beta-values 
were typically around 0.5 for HM450. Functional median sequencing depth (uniquely mapping 
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fragments) was approximately 4 million (interquartile range 3.4–5.8 million), and ranged up to 16.5 
million fragments. The average (standard deviation) MethylCap-seq coverage for the assessed HM450 
loci was 0.60 (0.33). Since coverages were too low for a quantitative comparison, we particularly focused 
on the inherent capacity of each methodology to detect methylated loci. As explained in the methods 
section, for MethylCap-seq, loci were considered to be methylated when at least one captured fragment 
could be mapped on that specific position.
MethylCap-seq - HM450 concordance depends on locus characteristics. First, concordance 
between both methodologies was evaluated by plotting the binary MethylCap-seq data as a function of 
HM450 beta-values (Fig. 1). Over all samples, the beta-values were binned (100 equidistant bins) and for 
each bin the average binary MethylCap-seq value (= fraction that was captured by MethylCap-seq) was 
plotted. An overview of the beta-value distributions is also displayed in Fig. 1, depicting the fraction of 
beta-values present in each bin, for each assay type. An almost linear trend to increasing MethylCap-seq 
capturing for higher beta-values was observed, with virtually no capture for the lowest beta-values.
Over all samples, up to 80% of those loci indicated to be heavily methylated by HM450 type 1 assays 
(beta-value ≅ 1) were also picked up by MethylCap-seq, whereas this was as low as 40% for HM450 type 
2 assays. This discrepancy between both HM450 assay types was also observed when considering the 
MethylCap-seq coverage values instead of the binary fractions (Supplementary Fig. S1). It can be hypoth-
esized that the lower concordance for type 2 assay probes might be attributed to an inherent lower quality 
of these probes, in line with the already reported results12,13. On the other hand, type 2 assay probes have 
been designed to assess different genomic regions than type 1 probes, featuring different characteristics 
such as a significantly lower content of CpGs (median 4 vs. 7 for type 1, P < 2.2E-16). The lower con-
cordance could therefore also be explained by the documented CpG22,23 and GC23,24 content biases of the 
MethylCap-sequencing methodology, providing an alternative hypothesis for our observation.
Therefore, we evaluated whether there was an effect of assay type on data quality by studying the 
concordance between HM450 and RRBS data generated by the ENCODE consortium25 for three cell 
lines (see Materials and Methods). Data were plotted in a similar fashion as visualized in Fig.  1, but 
raw HM450 methylation degrees were averaged for 5% beta-value bins. The comparison revealed that 
concordance was slightly higher for type 2 assay probes (Fig. 2), as was also observed for each individ-
ual cell line (data not shown). This indicates that the observed assay type effect can be attributed to 
MethylCap-seq specific biases, most likely related to the CpG- and GC-content of the broader probe 
target region, which might respectively affect the capturing and sequencing steps22–24.
Although overall correlation between HM450 and RRBS results was very good (Spearman correla-
tion, type 1 assay: rho ~0.77, type 2 assay: rho ~0.89, all P < 2.2E-16), it is clear from Fig. 2 that HM450 
beta-values also provide biased estimates of the actual methylation degrees, as probably more accurately 
reflected by the bisulfite sequencing data. Since both MethylCap-seq and HM450 methodologies have 
inherent strengths and weaknesses, neither can be considered as gold standard to assess sensitivity and 
specificity. Ideally, an independent gold standard methodology such as whole genome or reduced rep-
resentation bisulfite sequencing should be used. However, beside the fact that bisulfite sequencing has its 
own limitations, the application on 70 samples for mere validation purposes is practically and financially 
Figure 1. Concordance between MethylCap-seq and HM450 results. The fraction of fragments captured 
by MethylCap-seq (solid lines) are plotted as a function of HM450 methylation degrees (beta-values, binned 
per 1%), for both types of HM450 assays: type 1 (blue), type 2 (orange), and combined (black). The beta-
value distributions are depicted as dashed lines for both types individually (type 1, blue; type 2, orange) and 
combined (black).
www.nature.com/scientificreports/
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not feasible. Therefore, a Bayesian modeling procedure26 was applied that avoids the selection of one 
methodology as reference. Bayesian estimation is known to be a valuable method to assess the unbiased 
conditional sensitivity and specificity without external standard26–29.
Conditional sensitivity and specificity assessment of both methodologies. For the Bayesian 
analyses, also the HM450 data were dichotomized, using three different thresholds (beta-values of 0.2 
to 0.4) for absence/presence of methylation. The two HM450 assay types were treated separately. A 
beta-value threshold of 0.1 was also evaluated but yielded discrepant results and appeared to be too low 
to define methylation status, in particular for type 2 assays (data not shown). Two samples with low 
MethylCap-seq sequencing depths were not considered here, as these would also be removed in normal 
experimental settings (< 2 million mapped fragments). For each assay type and beta-value threshold pre-
sented, moderately to very good converging models were obtained for > 90% of the remaining samples, 
indicating overall reliable parameter estimates. The lack of convergence of some models appeared to be 
more frequent for beta-value thresholds of 0.1 (data not shown) and 0.2 (Supplementary Fig. S2 and S3).
Results for sensitivity and specificity are presented for each assay type separately in Table 1. Differences 
mentioned infra are absolute differences (but mentioned as percentages as also specificity and sensitiv-
ity are indicated as percentages). Stated significant differences were so for each beta-value threshold at 
the 0.005 level (paired t-test, paired on sample). Overall, specificity and sensitivity results estimated by 
Bayesian models appear to be roughly similar for the different thresholds (maximal difference 5%). As 
expected, the estimated true prevalence of methylation, i.e. the number of methylated loci, decreased 
for increasing beta-value thresholds. Sensitivity and specificity appeared to be clearly dependent on 
methodology but also on assay type. For HM450, significantly higher sensitivities (~15%) and (slightly) 
lower specificities (~5%) were observed for type 2 assay loci. In line with results mentioned above, 
MethylCap-seq sensitivities were significantly lower for type 2 assay loci (~18%).
Overall, specificity was adequate for HM450 (> 80%), but significantly higher for MethylCap-seq 
(> 92%), implying a high ability to correctly classify unmethylated CpGs for both platforms. Whereas 
mean sensitivity values for HM450 were satisfying for type 1 assay loci (> 70%) and good for type 
2 assays (> 87%), mean values for MethylCap-seq were significantly inferior: low for type 1 assays 
(> 50%) and clearly poor for type 2 assays (32–36%). However, the major differences between minimum 
and maximum sensitivities for MethylCap-seq (Table  1) suggest that varying sequencing depths (cf. 
Supplementary Table S1) may have an impact.
Using a beta-value threshold of 0.3, Fig. 3 (includes 2 low coverage samples for graphical purposes) 
indicate that this is indeed the case. Of note, sensitivity reaches a plateau phase for sufficiently large 
sequencing depths. Indeed, a maximal sensitivity of about 65% (type I)/55% (type II assay loci) is obtained 
for sequencing depths larger than ~8 million fragments. As expected, specificity tended to decrease for 
higher sequencing depths, but stays clearly above 90%. For beta-value thresholds of 0.2 and 0.4 the same 
trends were observed, with a little lower (~5%) and marginally higher (~2%) maximal sensitivity values 
for thresholds 0.2 and 0.4, respectively, and specificities consistently above 90%.
To illustrate this methodological comparison in the context of a clinically highly relevant gene in 
glioblastoma, the binary MethylCap-seq and HM450 data were compared with calls obtained for the 
Figure 2. Concordance between RRBS and HM450 results. The average RRBS methylation degree is 
plotted as a function of methylation degrees (beta-values, binned per 5%) for both types of HM450 assays: 
type 1 (blue) and type 2 (orange), and combined (black). The green line reflects unbiased concordance 
between both methods (theoretical).
www.nature.com/scientificreports/
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O6-methylguanine methyltransferase (MGMT) gene using methylation specific PCR (MSP)30. MSP data 
were available for 66 matching samples. The type I probe cg12981137 in the CpG island of MGMT inter-
rogates a CpG comprised in the reverse primer of the MSP assay31, while encompassing an additional 5 
CpGs, of which 2 are overlapping with the forward MSP primer. The kappa values were 0.76, 0.69 and 0.66 
at cut–offs of 0.2, 0.3 and 0.4, respectively, for the HM450 probe and 0.48 for the matched MethylCap-seq 
Beta Stat. Method
Type 1 chemistry loci Type 2 chemistry loci
Mean (SD) Min. Max. Mean (SD) Min. Max.
0.2 Prev. – 54.0 (3.3) 48 60.9 79.5 (1.5) 75.6 83.0
Sens. HM450 76.8 (2.1) 71.6 80.9 91.3 (0.9) 89.3 93.6
Spec. HM450 85.7 (1.0) 83 87.6 80.3 (0.8) 78.3 82.1
Sens. MCap 50.1 (9.2) 24.7 67.1 32.8 (8.7) 14.1 52.0
Spec. MCap 94.1 (1.3) 90.6 97.1 93.4 (1.1) 90.9 95.3
0.3 Prev. – 51.5 (3.5) 44.5 60.0 75.3 (2.1) 69.6 78.5
Sens. HM450 74.3 (2.5) 66.5 79.0 89.5 (1.2) 87.2 92.1
Spec. HM450 86.8 (1.1) 84.5 89.5 81.0 (0.9) 79.2 83.7
Sens. MCap 52.5 (9.0) 26.0 68.1 34.5 (9.3) 15.0 57.6
Spec. MCap 93.8 (1.4) 90.5 96.9 93.1 (1.4) 89.5 96.2
0.4 Prev. – 49.4 (3.9) 41.1 59.1 71.2 (2.9) 63.0 77.5
Sens. HM450 71.8 (2.6) 65.2 77.5 87.8 (1.4) 84.2 90.9
Spec. HM450 87.7 (1.2) 85.4 90.4 81.6 (0.9) 79.7 83.8
Sens. MCap 53.9 (8.5) 27.1 68.5 35.8 (9.4) 15.6 59.8
Spec. MCap 93.1 (1.7) 88.8 96.7 92.8 (1.5) 89.3 95.7
Table 1.  Gold standard independent DNA-methylation prevalence estimation, and sensitivity and 
specificity estimation for HM450 and MethylCap-seq. Data indicate mean (standard deviation, SD) and 
minimum (min.) and maximum (max.), over the different samples, for different statistics (stat.) for both 
methods (MCap indicates MethylCap-seq): methylation prevalence (prev.), sensitivity (sens.) and specificity 
(spec.) for both chemistries and different HM450 beta-value thresholds (Beta) for presence of methylation. 
Models presenting strong convergence problem and two samples with very low coverage (samples 38 and 43, 
Supplementary Table 1) were not considered in the estimation of the statistics. Nevertheless, for each statistic 
at least 90% of the samples were used.
Figure 3. MethylCap-seq sensitivity reaches a plateau phase for increasing sequencing depths. 
Conditional sensitivity (squares) and specificity (triangles) are plotted as a function of sequencing depth, for 
both HM450 type 1 (blue) and type 2 (orange) assay types. Loess regression curves (using span smoothing 
parameter 0.95) have been added for both sensitivity (solid lines) and specificity (dashed lines) for both 
HM450 assay types.
www.nature.com/scientificreports/
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site. In accordance with our previous results, a higher conditional sensitivity was observed for HM450, 
and a slightly higher conditional specificity for MethylCap-seq (no false positive vs 2, 1, and 0 for resp. 
HM450 cut-offs 0.2, 0.3 and 0.4) (see Supplementary Table S2).
Quantitative and functional genome-wide features. Whereas MethylCap-seq exhibited a mark-
edly lower sensitivity than HM450 for the loci assessed by the latter, this methodology is not limited by 
probes and can therefore interrogate more comprehensively “genome-wide” features. Therefore, it was 
evaluated to what extent methylated regions detected by MethylCap-seq were also assessed by HM450 
probes. For each sample, MethylCap-seq methylated regions were identified as stretches of the genome 
featured by a positive number of mapped fragments separated by at least one nucleotide without mapped 
fragments.
The ratio of the number of probe loci with non-zero coverage and the total number of MethylCap-seq 
methylated regions for each sample thus provides an indication of the genome-wide characterization 
by HM450 vs. MethylCap-seq. This comparison revealed that only about 7.5% (median, IQR = [6.3%–
9.8%]) of methylated regions identified by MethylCap-seq were also assessed by HM450. Of note, the 
use of ratios implicitly results in an adjustment for MethylCap-seq sequencing depth differences. Indeed, 
the ratios were not correlated with the sequencing depth (Spearman correlation, P = 0.42). Despite the 
detection of more methylated regions by MethylCap-seq, this does not automatically imply that also 
more relevant information will be retrieved.
Therefore, it was also evaluated to what extent the loci assessed by both methodologies differed with 
respect to CpG-island context and genomic functional location. For MethylCap-seq, the annotation of 
the center of the methylated regions was considered. Although no specific locations are targeted by 
MethylCap-seq, it should be noted that this approach is not completely unbiased due to the GC- and 
CpG-content dependent affinity of this method. Both for CpG-island context and genomic functional 
location, proportions of the features differed significantly between HM450, MethylCap-seq and their 
overall genomic distribution (Chi-square test, all P < 2.2E-16).
This confirmed that the HM450 probe locations have specifically been selected towards CpG-islands 
and associated shores and shelves (Fig. 4A), as described elsewhere14. Also for MethylCap-based results 
(Fig. 4C), in comparison with the genome-wide occurrence of these features (Fig. 4E), there is apparent 
enrichment for CpG-islands, shores and shelves. For MethylCap-seq, variation in function of sequencing 
depth were very limited, with a slight decrease in CpG-island, shore and shelve fractions and an increase 
for the open sea fraction for higher sequencing depths (Supplementary Fig. S2, panel A), in line with 
the slightly decreasing specificity for increasing sequencing depths. When evaluating absolute numbers 
of detected methylated loci, using a beta-value threshold of 0.3 for HM450, the latter method detects 
more methylated loci in CpG-islands, but clearly less methylated loci in CpG-island shore and shelve 
regions (Table 2). Only considering MethylCap-seq samples with high sequencing depths did not alter 
these conclusions, nor did the application of other beta-value thresholds for presence of methylation 
(data not shown).
When compared with the distribution of genome-wide functional annotation (Fig. 4F), the HM450 
predominantly targets promoters and exons (Fig. 4B), whereas MethylCap-seq data are enriched for the 
full length of the gene, including introns (Fig. 4D). Similar to the CpG-island context results, the propor-
tion of intergenic regions picked up by MethylCap-seq increased with higher sequencing depths, whereas 
the different gene-associated functional genome annotations slightly decreased (except for the intron 
fraction, Supplementary Fig. S4, panel B). In absolute numbers, more methylated loci were detected 
for each functional annotation class by the MethylCap-seq methodology (Table 2), including promoter 
regions.
Detection of differentially methylated loci. A comparison of methodologies may also include an 
assessment of the number of differentially methylated regions (DMRs). First, we assessed the intrinsic 
capacity of each methodology to detect potentially relevant loci, i.e. loci that were independently deter-
mined to be likely differentially methylated. Next, it was assessed whether this was also reflected in more 
significant differences between control and tumour samples in the dataset at hand.
As a proxy for “potentially relevant loci”, we evaluated to what extent HM450 and MethylCap-seq 
assess the set of genomic regions featured by dynamic DNA methylation, i.e. candidate DMRs (cDMRs) 
that were identified using 42 whole-genome bisulfite sequencing data sets by Ziller et al.7 Of the 485,512 
cytosines targeted by HM450, no less than 160,481 (33.1%) can be found in such a cDMR. However, in 
total only 63,590 (8.9%) of the 716,087 cDMRs were covered by a HM450 assay (for at least one CpG). As 
not all cDMRs can be expected to be methylated in the sample set under consideration, only a lower limit 
estimation is possible for MethylCap-seq. On the other hand, considering all covered cDMRs would yield 
an overestimation due to the presence of non-specific signal. Taking into account the (minimal) speci-
ficity of 90% for MethylCap-seq in this study (see above), a CpG can be considered to be significantly 
methylated if fragments were picked up for this CpG in at least 12 out of 70 samples (significantly higher 
detection rate than 10% at α = 0.05, binomial distribution). Using this definition, significant methylation 
was picked up by MethylCap-seq in 353,873 (49.4%) of the cDMRs (for at least one CpG). Using a more 
stringent criterion, i.e. significant methylation in at least half of the CpGs in the cDMR, 170,384 (23.8%) 
of all cDMRs were identified as methylated, which is still clearly more than the potential of HM450.
www.nature.com/scientificreports/
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Subsequently it was assessed whether this additional potential for MethylCap-seq also resulted in more 
significant differences between the 5 control and 63 glioblastoma samples. As in the previous section, 
two MethylCap-seq samples with lowest sequencing depths were not considered. For MethylCap-seq, 
the cDMRs identified by Ziller et al.7 were considered as variables. The same methodology was used for 
both datasets to enable an objective comparison. As outlined in the Methods section, dichotomized data 
(using 0.3 as cut-off for HM450) were compared using the Fisher exact test, and a permutation approach 
was used to obtain an estimate of the number of significant loci at a false discovery rate of 0.05.
This supervised analysis indicated that far more significant loci were found for HM450 (14,434) than 
for MethylCap-seq (233). Of the latter 233 regions, only 5 were targeted by one or more Infinium probes 
(9 probes in total), of which only one, cg21691166 (an intergenic probe targeting a locus near SLC14A1), 
was also significant by Fisher exact test analysis in the HM450 dataset (P = 0.009; Supplementary Tables 
S3 and S4). However, when performing a quantitative comparison for these 9 probes by the Welch t-test 
on the HM450 M-values, 7 out of 9 yielded a significant outcome (Supplementary Table S3), indicating 
that the selected data-analytical methodology (dichotomization procedure) rather than exact probe loca-
tion or presence of noise and biases is the most important underlying cause of this apparent discrepancy. 
A comparison of the annotation for the significant loci indicated major differences in CpG and func-
tional location context between HM450 and MethylCap-seq results (Supplementary Table S5), which 
however predominantly reflect the overall differences between both platforms as discussed above (Fig. 4). 
In line with the limited overlap of significant results between both platforms, numbers and fractions of 
significant results stratified per chromosome exhibited low similarity as well (Supplementary Table S6).
Additionally, it was assessed whether there was also a global difference between tumours and controls: 
upon principal coordinate analysis (PCO) of both binary datasets, permutations were used to infer the 
Figure 4. Fractions of CpG-island and functional location context assessed by both methodologies. 
Fractions of loci corresponding to CpG-islands, shores, shelves and open sea and fractions of promoter, 
exon, intron, pseudogene and intergenic loci assessed by HM450 (A,B) and detected by MethylCap-seq 
(C,D) and their genome-wide distribution (E,F).
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significance of this overall difference between both sample groups. Also here, this difference was present 
for both methodologies (Supplementary Fig. S5), but was more significant for HM450 (P < 0.001) than 
for MethylCap-seq (P = 0.009).
It is clear that in this particular experimental setting, both supervised and unsupervised results sug-
gest that HM450 is able to detect more putatively relevant variation, i.e. discriminating between tumours 
and controls, than MethylCap-seq.
Discussion
In this manuscript, MethylCap-seq and Infinium HM450 BeadChip data were compared for a large set 
of 70 brain tissue samples, mostly glioblastoma. The DNA used was obtained from the same DNA isolate 
for both methodologies. Overall, results were concordant, although this was to a lesser extent the case 
for Infinium type 2 assay loci, due to MethylCap-seq dependent biases. This is most likely related to the 
CpG- and GC-content of the broader probe target region, which might respectively affect the capturing 
and the sequencing steps of the MethylCap-seq procedure22–24. It is of note that MethylCap-seq sequenc-
ing depths were limited, we therefore focused on the detection of methylated loci rather than proceeding 
to a quantitative analysis, which is certainly a limitation of this study.
To assess conditional sensitivity and specificity for both methods, a Bayesian modelling procedure was 
used that does not rely on the comparison to a gold standard methodology. The latter would have been 
optimally suited for such an analysis yet was practically infeasible taking into account the large number 
of samples. It was clear that the sensitivity of MethylCap-seq to detect methylated loci was lower than 
for Infinium HM450, i.e. MethylCap-seq fails to detect a substantial part of methylated CpGs, and this 
was more prominent for only partially methylated alleles. Specificity was adequate for both methodol-
ogies, and higher for MethylCap-seq, although this difference was attenuated by higher MethylCap-seq 
sequencing depths. Sequencing depth also affected MethylCap-seq sensitivity, and we demonstrated that 
with approximately 8 million of fragments, maximal sensitivity regarding the detection of methylated 
loci is obtained. Importantly, this indicates that some methylated fragments are virtually impossible 
to capture or sequence by MethylCap-seq, even when one would use sequencing depths substantially 
higher than obtained in the here reported experiment. The previous comparison by Bock et al. already 
demonstrated (slightly) lower accuracy for MethylCap-seq than for HM27, which only contains type 1 
assay loci22. Our results are in line with this observation for type 1 loci, but also show that sensitivity, and 
therefore overall accuracy, is even far lower for type 2 assay loci, most likely due to the specific sequence 
characteristics. As the sensitivity of MeDIP-seq also depends on CpG density, with inconclusive results 
whether this dependency is higher than for MethylCap-seq32,33, it is unlikely that this alternative enrich-
ment based procedure might provide a far better solution.
We applied a modelling approach to estimate (conditional) sensitivity and specificity, which is a well 
substantiated strategy when an appropriate gold standard or reference is lacking26–29. In the large majority 
of the parameter estimation models, convergence was obtained, and results were overall very consistent. 
Moreover, in the population under study, overall conclusions were in line with MSP results for MGMT 
methylation, a highly relevant biomarker in glioblastoma30. This indicates that the Bayesian estima-
tion approach provided indeed an appropriate yet affordable alternative for expensive, putatively “gold 
standard” methods such as RRBS. However, even with this alternative solution at hand, more extensive 
Feature HM450 MethylCap-seq
Sign. 
diff.
CpG-island context
 CpG-islands 44,480 [41,357–47,161] 17,679 [15,310–21,139] 3.6E-13
 Shores 71,157 [69,366–72,560] 95,552 [85,317–111,682] 2.5E-10
 Shelves 44,262 [43,576–44,666] 78,239 [68,305–92,023] 8.9E-12
 Open sea 155,028 [150,657–157,864] 1,495,205 [1,140,952–1,885,495] 4.0E-13
Functional genomic location context
 Promoters 64,759 [63,112–66,207] 113,817 [96,797–137,230] 9.2E-12
 Exons 62,123 [61,246–63,027] 97,737 [85,470–115,403] 2.4E-11
 Introns 115,779 [113,247–117,296] 817,975 [649,211–1,026,661] 4.0E-13
 Pseudogenes 1,058 [1,048–1,070] 4,512 [3,637–5,384] 4.3E-13
 Intergenic 71,120 [69,181–72,292] 643,160 [479,131–816,080] 4.0E-13
Table 2.  Comparison of the numbers of methylated loci, stratified by functional annotation, between 
HM450 and MethylCap-seq. Data indicate median [IQR (interquartile range)] numbers of methylated loci 
detected for the 70 samples, significance of the differences (sign. diff.) between absolute numbers for both 
methodologies was evaluated with the Kruskal-Wallis signed rank test. A beta-value threshold of 0.3 was 
used for presence of methylation for HM450.
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validation using an independent methodology remains to be the preferred strategy. One additional dis-
advantage is the need for considering methylation as a qualitative feature (absent/present).
Alternatively, quantitative assessment is possible for HM450 but also for MethylCap-seq. However, the 
sequencing depth was too limited in our study to fully exploit its potential, which is an important limita-
tion of this study. On the other hand, from a practical point of view, in most studies DNA-methylation is 
considered as a qualitative phenomenon, imposing e.g. a minimal beta-value threshold for methylation, 
and using methylation specific PCR for validation purposes. Of note, for a quantitative approach to 
MethylCap-seq (or MeDIP-seq) based results, adjustment for locus-dependent biases (such as GC% and 
CpG-content) is absolutely necessary using algorithms such as BATMAN34.
Since shifts in parameter estimates (Table  1) were clearly larger between beta-value thresholds 0.2 
and 0.3 than between 0.3 and 0.4, a threshold of 0.3 appears to be more suitable and this threshold was 
selected for the subsequent analyses. Although different thresholds might be appropriate for the two 
assay types due to the distinct beta-value distributions (cf. Fig. 1), a threshold of 0.3 appears to be a good 
consensus. Alternatively, data transformations can be used that increase overall correspondence between 
both HM450 assay type beta-value distributions or decrease overall technical artefacts12,13,35, but as raw 
data are already highly reproducible16 we elected to avoid data transformation and perform the analyses 
for both assay types separately.
Similarly, also other data preprocessing steps (e.g. probe filtering15, advanced background correction36, 
methylation status determination by mixture modeling17) and transformations (e.g. use of M-values37) 
and their combinations might improve results for HM450. Also here, we elected to avoid these often 
useful data modifications as these advanced methods either i) try to remediate inherent drawbacks of 
the methodology under evaluation, e.g. probe filtering15, ii) are not generally implemented (and often 
not independently validated), e.g. methylation state modeling, or iii) are not readily relevant for our 
goals, e.g. despite their less intuitive character, M-values are better for differential analysis of methyla-
tion levels37, but as these values are obtained by a monotonous transformation of β-values, β-value and 
M-value cut-offs yield equivalent results. Moreover, in all cases, results are clear to an extent that further 
data-analytical improvements will only have low impact. There are also experimental factors that could 
potentially have an impact on our conclusions regarding sensitivity and specificity. Indeed other potential 
sources of variation for the MethylCap-seq methodology are the capturing step of methylated fragments, 
i.e. the specific kit or methyl-binding domain used, as well as the salt concentration in the elution step. 
An initial evaluation suggested that the used MethylCap-seq kit yielded by the highest sensitivity and 
specificity, as independently evaluated by RRBS and HM2738. Also, as a single, high-salt elution was 
used for the MethylCap step, those fragments that are rather difficult to capture (e.g. featured by a 
lower CpG methylation degree) should have already been included. This implies that the used protocol 
already aimed for a maximal sensitivity. In addition, the difference in sensitivity between HM450 and 
MethylCap-seq regarding the detection of methylated loci was clear to an extent that it is very unlikely 
that different kits and validation methods would have a profound impact on this conclusion. Also, this is 
the first study performing a large-scale evaluation (70 samples) of both methodologies, providing major 
support to the reliability of our results, even when considering the limitations associated with the lack 
of a gold standard and the use of dichotomized data.
Sensitivity can also be considered from a “genome-wide” perspective, i.e. the number of loci identified 
to be methylated by a certain methodology. It is clear that MethylCap-seq has the inherent potential to 
detect far more methylated loci than the Infinium HumanMethylation BeadChip methodology, also in 
genomic regions that can be assumed to be biologically relevant (e.g. differentially methylated between 
case and control). However, in the current study, MethylCap-seq did not yield a better discrimination 
between both sample groups than HM450. In part, this can be attributed to the lower sensitivity of 
MethylCap-seq, implying that higher sequencing depths and a more balanced study design are required 
to obtain more significant results. The very large numbers of DMRs in combination with the clear PCO 
based separation of both sample groups for HM450 may also indicate that a clinically relevant fraction 
of glioblastoma samples are featured by a CpG island methylation phenotype (“G-CIMP”), leading to 
major global differences in methylation39. As MethylCap-seq is an enrichment based methodology, it 
is far less capable of detecting these global differences. Additionally, it should be noted that this would 
also imply violation of the independence assumption for false discovery rate estimation (see Methods), 
leading to an anti-conservative estimate of the number of significant genes, particularly for HM450. As a 
final remark in this comparison, although not directly related to here described results, it should be noted 
that a major advantage of MethylCap-seq over BeadChips is that the latter is human specific, whereas 
MethylCap-seq is more broadly applicable.
In conclusion, a comparative analysis revealed that HM450 and MethylCap-seq are rather comple-
mentary methods for the genome-scale detection of DNA-methylation. At least for this collection of 
brain samples (mostly glioblastoma), both exhibit high specificity, and while MethylCap-seq suffers from 
a lower sensitivity, it displays a far larger genome-wide potential for discovery. However, MethylCap-seq 
did not yield more DMRs in the study at hand, suggesting that more power and higher sequencing 
depths are required for MethylCap-seq to exploit this potential. Also, our results indicate that even with 
very high sequencing depths it is virtually impossible to profile all methylated loci in the human genome 
using MethylCap-seq. Additional validation, preferably featured by higher MethylCap-seq coverages and 
an independent gold standard methodology, is warranted to fully substantiate this claim.
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Methods
Samples and DNA-isolation. DNA-methylation profiles were established for 65 glioblastoma tissues 
and 5 non-tumoral brain tissues (epilepsy surgery). All glioblastoma patients were treated within clinical 
trials (TMZ/RT pilot study40; EORTC Study 26981, www.clinicaltrials.gov, NCT#0000635341) and all sub-
jects provided informed consent for molecular studies of their tissues, the trials conducted accruing to 
the approved good clinical practice guidelines and the Declaration of Helsinki; the clinical protocols were 
approved by the ethics committees at each participating center and the respective competent authorities. 
The use of biological material was approved by the Ethics committee of Canton of Vaud, Lausanne, 
Switzerland (approval F25/99/ Commission cantonale d'étique de la recherche sur l'être humain, canton 
de Vaud, Lausanne Switzerland).
Description of the samples has been published previously40–42. Methods have been carried out in 
accordance with approved guidelines. DNA was isolated from snap frozen samples using a genomic DNA 
isolation kit including an RNase treatment step (Qiagen kit 19060). DNA was obtained from the same 
isolate for the HM450 and MethylCap-seq assays, implying no differences due to tumour heterogeneity.
HM450 assay. For each sample, 1.0 μ g of DNA was bisulfite converted using the EZ DNA Methylation 
Kit (Zymo Research) and analyzed on HM450 BeadChips at the University of Gevena’s Genomics plat-
form, both according to the manufacturers’ instructions. The Illumina GenomeStudio program was 
used for normalization and extraction of the methylated and unmethylated signal intensities. The 
probes’ characteristics were derived from the IlluminaHumanMethylation450k.db Bioconductor pack-
age. Probes without annotation (chromosome/locus) were removed, yielding a final dataset consisting of 
485,512 assessed loci. For all samples, detection P-values were lower than 0.05 for over 99.9% of all loci; 
non-significant loci (P > 0.05) were not considered in the subsequent analysis. There is no consensus 
regarding beta-value cut-off values for presence of methylation, although typically thresholds of 0.2 and 
0.3 are used37,43. To take into account variation of this arbitrary threshold, a range of 4 cut-offs (0.1 to 
0.4) was used. However, as the 0.1 threshold was clearly too low to obtain reliable results, data for this 
threshold have been omitted from this manuscript.
MethylCap-seq. A full description of the MethylCap-seq procedure can be found in De Meyer 
et al.38, with minor modifications as mentioned infra. In summary, 500 ng of DNA per sample was frag-
mented by ultrasound mediated DNA shearing (Covaris S2, Covaris, Woburn, Massachusetts, USA) 
set to obtain fragments with an average length of 200 bp. We employed the MethylCap kit (Diagenode 
AF-100-0048, Liège, Belgium) to obtain methylated DNA fragments using the highest salt concentra-
tion single elution step option. This was followed by the library preparation for the enriched DNA, 
which was performed with a modified ‘multiplexed paired-end ChIP protocol’ (Illumina, San Diego, 
California, USA). Therefore, the NEBNext® DNA Sample Prep Master Mix Set 1 (New England BioLabs 
(NEB) E6040, Ipswich, Massachusetts, USA) was combined with the Multiplexing Sample Preparation 
Oligo Kit (Illumina PE-400–1001). Per sample, 22 μ l of the prepared sample was subjected to PCR (21 
cycles) following the Illumina Library Amplification Index Protocol. After purification (Qiaquick PCR 
Purification columns, Qiagen), elution and concentration (evaporation), the libraries were pooled and 
denaturated (NaOH), followed by Illumina GAIIx sequencing (‘multiplexed paired-end run, 2 times 45 
cycles) of 10pM/pool.
Sequence data was processed with an in house developed pipeline using Perl 5.12.2. Paired-end reads 
were mapped using BOWTIE44, and only fragments for which reads mapped uniquely within a 400bp 
of each other in the human reference genome (NCBI build 37) were retained. Fragments for which 
paired-end reads mapped on exactly the same locations were considered as PCR duplicates and further 
treated as a single fragment. Loci were considered to be methylated if at least one fragment could be 
mapped on that position.
ENCODE data. For independent validation of observed phenomena, RRBS and HM450 data gen-
erated by the ENCODE consortium25 were downloaded for cell lines HCT-116, Caco-2 and MCF-7, 
originating from Stanford University, University of Washington and Duke University (http://encodepro-
ject.org/ENCODE/downloads.html, replicate 1 for each cell line), respectively. Following the ENCODE 
recommendations, only CpGs with a minimal RRBS coverage of 10 were included in the analysis. For 
HCT-116, Caco-2 and MCF-7, respectively 18,168, 40,782 and 31,183 loci were identified that overlapped 
between both methodologies.
Bayesian modeling to estimate conditional sensitivity and specificity. Uncertainty related to 
the choice of the threshold for dichotomization of the HM450 data and the presence of other biases also 
implies that neither platform can be considered as gold standard for the definition of the methylation 
status of a given CpG. Consequently, a Bayesian modeling procedure was used to estimate the median 
of the sensitivity, specificity and the true prevalence for each sample and each beta threshold. We used 
the alternate parameterization proposed by Dendukuri and Joseph27, and used by de Clare Bronsvoort 
and coworkers28, for the two dependent tests, one population scenario. The model, based on a multino-
mial likelihood function, involves the estimation of seven parameters: sensitivity and specificity for each 
method, methylation prevalence and covariances between the two methods among the methylated and 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 5:15375 | DOi: 10.1038/srep15375
unmethylated CpG. The implementation and properties of this model have been described in detail by 
Dendukuri and Joseph27 and Branscum et al.26 Because the model was non-identifiable, the initial con-
ditions were redefined with different prior values for each Markov Chain. Besides visual inspection of 
the MCMC chain, we computed the Gelman and Rubin Rˆ statistic as convergence measure29. Rˆ provides 
an easy–to–interpret measure of whether independent chains have converged to sample from the same 
distribution. After convergence, Rˆ should be very close to 1 (as a rule of thumb, smaller than 1.1) for all 
parameters indicating good mixing of the chains and thus approximate convergence. The Bayesian model 
was performed in the freeware program WinBUGS45 (version 1.4.3) and R package R2WinBUGS46. The 
estimations were obtained after 200,000 iterations for five Markov chains with different starting positions, 
of which only the second half of the iterations was considered to be representative of the stationary 
distribution of the chains, in order to obtain accurate inference from the Gibbs sampler.
Loess regression and functional annotation information. Additional data-analysis was per-
formed in the R statistical environment, version 2.15.2. For loess regression, the R “stats” package func-
tion “loess” was used. CpG-island annotation was downloaded from UCSC (http://hgdownload.cse.ucsc.
edu/, latest version - April 13, 2006). Using common definitions, e.g. by Pan and colleagues11, CpG-island 
shores were defined as those regions up to 2 kb up- or downstream from the CpG-island start and end, 
respectively. The regions another 2 kb up- or downstream from the shore boundaries were defined as 
CpG-island shelves. The remaining fraction of the genome was annotated as “open sea”.
Functional genomic information was downloaded from Ensembl’s Biomart database (accessed on 
January 9, 2013). As we aimed at a comparison between methodologies, relatively arbitrary definitions 
could be used. Promoter regions were defined as those regions 1.5 kb upstream to 0.5 kb downstream 
of the transcription start site (taking into account direction of the transcript) of all transcripts in the 
database. All regions annotated as such were considered as exon, except for the parts overlapping with 
promoter regions. Other regions within the gene boundaries can generally be considered as intronic, and 
were annotated as such. The pseudogene annotation by Ensembl was followed, but regions overlapping 
with non-pseudogenes were truncated.
Detection of differentially methylated regions and global methylation differ-
ences. Differentially methylated regions were assessed by the Fisher exact test on the dichotomized 
data sets (beta-value cut-off of 0.3 for HM450), considering solely those loci that were not consist-
ently methylated or unmethylated in all samples under study (162,872 loci for HM450, 660,983 for 
MethylCap-seq; two samples with lowest MethylCap-seq sequencing depths were not included in these 
analyses). As most false discovery rate estimation strategies use assumptions that are not valid for these 
non-continuous data, a permutation based approach was used to obtain a P-value distribution under the 
null hypothesis.
For each locus in the data set under study individually, class labels were permuted, leading to a 
randomized dataset that should contain virtually no association with the phenotype, but still has the 
same average methylation frequency per locus. Subsequently, upon ranking of the P-values for the actual 
dataset, for each P-value, Pi – with i ranging from 1 to the number of loci considered, a corresponding 
false discovery rate can be calculated as the number of null P-values smaller than or equal to Pi divided 
by i. Note that this approach is based on the conservative assumption that the fraction of non-null loci 
equals 0 and that it ignores dependency between variables.
An alternative approach is to evaluate to which extent the major sources of variation in each data-
set are associated with the differences between case and control samples. Therefore, for each dataset, 
principal coordinate analysis (PCO)47 was performed on the Jaccard distances between samples48. A 
Monte-Carlo test (1000 permutations) on between-group inertia (global test) was performed to test the 
overall difference between tumor and control samples49. PCO, between-group tests and graphical rep-
resentations were performed using the “ade4” R package with standard options50.
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